Drug Patents in India Helping Promote Innovation
President of the Organization of Pharmaceutical Producers of India releases statement on Intellectual Property Day
Saint Louis, MO (PRWEB) April 30, 2010
Ranjit Shahani, President of the Organization of Pharmaceutical Producers of India (http://www. indiaoppi. com/) released the following statement on Intellectual Property Day concerning the effect drug patent protection is having on innovation in India:
Emotion tends to override facts when it comes to patents and patients' concerns. Consider the fears stoked when India joined the World Trade Organization in 1995. Many feared drug prices could rise, access to medicines could be reduced and many Indian pharmaceutical companies could close down.
Fifteen years later, these fears have proved unfounded: Drugs in each category are available at multiple price points, accessibility is clearly independent of patents, and Indian companies have become multinationals and entering foreign markets worldwide.
When India reinstated patent protection via IPR (intellectual property rights) reforms, many feared this would lead to decreased access to medicine and delayed entry of generic medicines. Despite the lack of pharmaceutical patents in India for 35 years and some of the lowest prices for medicine in the world, access to medicine in India remained among the lowest in developing nations. In other words, patents have little to do with the ability to access medicines.
While many try to point fingers at drug patents (http://www. thehindubusinessline. com/2010/04/26/stories/2010042650240900.htm) and IPR protection, the lack of healthcare financing and particularly health insurance are the real culprit. Limiting the types of innovations which receive patent protection, as India currently does, won't improve the health of Indians.
Small innovations that build on existing knowledge are the true backbone and a specific strength of the pharma industry. Yet, Indian laws prohibit certain types of pharmaceutical innovations from patent protection, thereby discouraging research. Indeed, this policy hurts Indian patients the most.
There are many meaningful benefits of continued research on existing medicines. For instance, drug formulations and delivery systems can be optimised for greater effectiveness in India's hot, humid climate. Paediatric formulations could be developed for babies suffering from diseases more often found in adults. It could also promote the development of treatment for diseases prevalent in India — tuberculosis, malaria, filariasis and other tropical diseases — where breakthroughs are unfortunately rare.
Innovation, research and patent protection are critical to introducing new drugs into the market. Innovations and effective drugs are inseparable, as diseases constantly mutate and many have inadequate treatments
Without patent protection, innovations decline, as R&D needs immense investments. Due to high, ever-increasing R&D costs, only two in 10 approved medicines earn more than the average cost of developing a new drug. Statistics are telling: a new drug discovery cost around $138 million in 1975, $318 million in 1987 and more than $1.3 billion in 2006.
The Prime Minister, Dr Manmohan Singh, has acknowledged the critical role of innovation at the 97th Indian Science Congress held in Thiruvananthapuram recently: “Our Government has declared 2010-20 as the ‘Decade of Innovations'. We need new solutions in many areas… in healthcare, in energy, in urban infrastructure, in water management, in transportation… The country must develop an Innovation Eco-system to stimulate innovations… And innovative solutions with potential must be nurtured and rapidly applied.”
As we take a look at drug patents on Intellectual Property Day, we must not forget the important role they play in keeping India and the world healthy. With viruses that mutate constantly — HIV/AIDS, H1N1, and TB — incremental innovations are imperative to stay one step ahead in the war against disease. If all innovations are protected to expand treatment options, millions of patients in India and worldwide will benefit. At stake are not just patents, but the lives of millions.
About Organization for Pharmaceutical Producers of India (OPPI)
The Organization for Pharmaceutical Producers of India, established in 1965, is a premier association of research based international and large pharmaceutical companies in India. It also serves as a scientific and professional body. It caters to the needs of Research based Pharmaceutical Industry thereby creating and sustaining an environment conducive to innovation and growth, simultaneously, facilitating industry and stakeholders partnership through various advisory and consultative processes to achieve the Healthcare objectives of the Nation. On the Web at http://www. indiaoppi. com (http://www. indiaoppi. com)
###
